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Objectives: In this study, we sought to compare the sterilizing activity of human-equivalent doses of the
‘Denver regimen’ against acute tuberculosis (TB) infection in the standard mouse model and in the guinea pig.
Methods: Pharmacokinetic studies in guinea pigs were used to establish human-equivalent doses for rifampi-
cin, isoniazid and pyrazinamide. Guinea pigs and mice were aerosol-infected with Mycobacterium tuberculosis
CDC1551 and treatment was started 2 weeks later with rifampicin/isoniazid/pyrazinamide for up to 6 months.
For the ﬁrst 2 weeks of therapy, the dosing frequency was 5 days/week, and for the remaining period, twice
weekly. Treatment was discontinued in groups of 30 mice and 10 guinea pigs at 5 months and at 6 months,
and these animals were held for a further 3 months in order to assess relapse rates.
Results: Guinea pig lungs became culture-negative after 3 months of predominantly twice-weekly treatment
and relapse rates were 0% (0/10) both after 5 months and after 6 months of treatment. In contrast, all
mice remained culture-positive despite 6 months of the same treatment, and 93% (28/30) and 69% (20/29)
of mice relapsed after treatment for 5 and 6 months, respectively.
Conclusions: Treatment with rifampicin/isoniazid/pyrazinamide administered at human-equivalent doses is
much more potent against acute TB infection in guinea pigs than in mice. Our ﬁndings have important
implications for the use of alternative animal models in testing novel TB drug regimens and for modelling
M. tuberculosis persistence.
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Introduction
Animal models have played a signiﬁcant role in the pre-clinical
assessment of drug candidates for tuberculosis (TB) treatment.
1
Although the guinea pig has historical precedence,
2 the mouse
has been the preferred model for chemotherapy studies since
the 1960s because of its reduced cost, robustness, ease of hand-
ling and ability to accurately emulate the activity of anti-TB drugs
in humans.
1,3 After a large intravenous or aerosol inoculation,
4,5
mice contain a peak lung burden of 10
8 bacilli, approaching
that of a human lung cavity
6 and permitting the evaluation of
whether a drug regimen is able to prevent the selection of
drug-resistant mutants and achieve culture conversion without
relapse upon treatment completion. Because of these features,
the mouse model has been considered essential for the
development of new anti-TB drugs.
1 However, mice infected
with Mycobacterium tuberculosis develop TB-related pathology
histologically distinct from human TB lesions and mice metab-
olize drugs differently from humans. In addition, although
highly intermittent regimens such as the ‘Denver regimen’
7 are
clinically effective in humans with non-cavitary TB, these regi-
mens are unable to sterilize the majority of mouse lungs follow-
ing 6 months of treatment,
5 suggesting that the standard mouse
model is overly ‘pessimistic’ with respect to predicting the
response to anti-TB therapy in humans.
Theguineapigmodel has been usedinthepast todemonstrate
successfully the anti-TB activity of streptomycin,
2 isoniazid
8 and
ethambutol,
9andtoevaluatetherespectivecontributionsofisonia-
zid, rifampicin and ethambutol when the drugs are given in combi-
nation.
10However,theguineapigremainspoorlycharacterizedasa
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729model of experimental TB chemotherapy. Previous guinea pig
studies have used variable infectious doses, routes of infection,
drug doses and incubation periods prior to treatment, rendering
direct comparisons between experiments difﬁcult and comparison
with the mouse model impossible.
1
As a ﬁrst step, we sought to compare directly the activity of
the ‘Denver regimen’ against acute TB infection in the guinea
pig and the mouse. This intermittent regimen consisting of
2 weeks of daily therapy followed by 24 weeks of twice-weekly
treatment (62 doses) was developed two decades ago by
Sbarbaro and colleagues
7 in an effort to facilitate supervision
of TB treatment and improve treatment completion rates
among medically non-adherent patients. Because of the
limited data available,
11–14we ﬁrst characterized the pharmaco-
kinetic (PK) parameters in the guinea pig of the standard anti-TB
drugs rifampicin, isoniazid and pyrazinamide to establish
human- and mouse-equivalent doses based on the area under
the serum concentration–time curve (AUC). Using similar lung
bacterial densities and equivalent drug doses, we then evaluated
the bactericidal and sterilizing activities of the standard short-
course regimen rifampicin/isoniazid/pyrazinamide against acute
TB infection in guinea pigs and mice. A high inoculum was
used to infect guinea pigs and mice in order to achieve
14 days later, at treatment initiation, a bacillary burden
approaching that of human pulmonary cavities.
6
Materials and methods
M. tuberculosis strains
Log-phase cultures of a virulent M. tuberculosis wild-type CDC1551
strain
15 were used for animal infections, as previously described.
16
Animals
Female outbred Hartley guinea pigs (250–300 g) with and without
jugular vein vascular catheters and female BALB/c mice (6–8 weeks
old) were purchased from Charles River (Wilmington, MA, USA). All
procedures were approved by the Institutional Animal Care and Use
Committee at Johns Hopkins.
PK experiments
Separate groups of three catheterized guinea pigs were given a single
dose of 50 mg/kg, 100 mg/kg or 150 mg/kg rifampicin (Bioworld,
Dublin, OH, USA) or 200 mg/kg, 300 mg/kg or 400 mg/kg pyrazinamide
(Acros Organics, Morris Plains, NJ, USA). Another group of animals
received 100 mg/kg rifampicin 1 h prior to concurrent dosing with
60 mg/kg isoniazid
15 and 300 mg/kg pyrazinamide. To enhance palatabil-
ity, doses of each drug were prepared in a homogeneous suspension of
40% sucrose (w/v) in a ﬁnal volume of 0.5 mL for each individual
guinea pig, and delivered in the posterior oropharynx by automatic
pipette with disposable tip, as previously described.
15 Blood (0.3 mL)
was removed serially from guinea pigs through the intravenous catheter
at the following timepoints after antibiotic dosing: 30 min; 1 h; 2 h; 4 h;
6 h; 8 h; 12 h; and 24 h. Serum was separated and frozen at 2808C
before analysis at Dr Peloquin’s Infectious Disease Pharmacokinetics Lab-
oratory.
15,17,18Serum rifampicin and isoniazid concentrations were deter-
mined using a validated HPLC assay comprising a ThermoFinnegan P4000
HPLC pump (San Jose, CA, USA) with model AS1000 ﬁxed-volume auto-
sampler, a model UV2000 ultraviolet detector, a Gateway Series e com-
puter (Poway, CA, USA) and the Chromquest HPLC data management
system. Serum concentrations of pyrazinamide were determined using
a validated gas-chromatography assay with mass selective detection
(Agilent 6890 GC and 5973 MS; Wilmington, DE, USA). The plasma stan-
dard curves for rifampicin, isoniazid and pyrazinamide ranged from 0.5 to
50 mg/L, 0.5 to 20 mg/L and 0.5 to 100 mg/L, respectively. The absolute
recoveries of rifampicin, isoniazid and pyrazinamide from plasma were
96%, 61% and 100%, respectively. The within-day precision [percentage
coefﬁcient of variation (CV)] of validation quality control (QC) samples for
rifampicin was 2.4%–4.6%, and the overall validation precision was
6.3%–7.1%. QC sample concentrations for rifampicin were 26, 8 and
3 mg/L. The within-day precision (%CV) of validation QC samples (13, 6
and 0.8 mg/L) for isoniazid was 1%–6%, and the overall validation pre-
cision was 6%–10%. Inter-day and intra-day precision values for QC
samples (16, 32 and 64 mg/L) for pyrazinamide were 2.2%–3.2% and
2.8%–3.3% CV, respectively. Serum concentration data were entered
into a WinNonlin worksheet (WinNonlin Version 5.2, 2008; Pharsight,
Mountain View, CA, USA) and analysed using standard non-
compartmental techniques to determine the relevant PK parameters.
Aerosol infections
Log-phase (A600 0.5) cultures of M. tuberculosis CDC1551 were
used undiluted for aerosol infection of mice and diluted 5-fold
(to 10
7 cfu/mL) in 1  PBS for aerosol infection of guinea pigs. Groups
of 77 guinea pigs and 115 mice were aerosol-infected separately with
these M. tuberculosis cultures using the Inhalation Exposure System
(Glas-Col, Terre Haute, IN, USA), which was calibrated to deliver
3.5 log10 cfu and 5 log10 cfu into the lungs of mice and guinea pigs,
respectively.
Antibiotic treatment
Chemotherapy was initiated 14 days after aerosol infection (on Day 0) in
each species. For the ﬁrst 2 months of treatment, both species were
given rifampicin/isoniazid/pyrazinamide and for the remaining 4 months,
only rifampicin/isoniazid. Dosing frequency was daily (5 days/week) for
the ﬁrst 2 weeks and then twice weekly for the remaining period
without modiﬁcation in dose size. Mice received 10 mg/kg rifampicin,
25 mg/kg isoniazid and 150 mg/kg pyrazinamide by oesophageal
cannula; guinea pigs received 100 mg/kg rifampicin, 60 mg/kg isoniazid
and 300 mg/kg pyrazinamide. In each species, the rifampicin dose pre-
ceded that of the other drugs by at least 1 h to limit drug interactions.
19
Groups of ﬁve mice and four guinea pigs were sacriﬁced at 2 weeks and
monthly thereafter up to 6 months after treatment initiation to assess
the bactericidal activity of the regimen. Treatment was discontinued for
groups of 30 mice and 10 guinea pigs at 5 months and at 6 months,
and each group of animals was sacriﬁced 3 months after discontinuation
oftreatmentinordertoassesstherelapserate,i.e.thesterilizingactivityof
the regimen. Relapse was deﬁned as positive culture upon plating entire
undilutedlunghomogenates.Mouseandguineapiglungswerehomogen-
ized as previously described.
15 Diluted and undiluted lung homogenates
were plated on Middlebrook 7H11 plates containing cycloheximide
(50 mg/L),carbenicillin(100 mg/L),polymyxinB(200 U/mL)andtrimetho-
prim (20 mg/L) for cfu enumeration. Log-transformed cfu values were
used to calculate averages and standard errors for graphing purposes.
Results
Identiﬁcation of the human-equivalent doses of
rifampicin and pyrazinamide in guinea pigs
Based on AUC/MIC, which appears to be the parameter most
closely correlated with the bactericidal activity of isoniazid,
20
the human-equivalent dose of isoniazid in the guinea pig was
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15 In the current study, we
evaluated the PK parameters of the companion drugs rifampicin
and pyrazinamide in the guinea pig (Table 1). After oral adminis-
tration of rifampicin in guinea pigs, the mean peak serum
concentrations (Cmax) were 2.9+2.0, 15.9+2.9 and
40.5+5.2 mg/L after 50 mg/kg, 100 mg/kg and 150 mg/kg
rifampicin, respectively. Corresponding AUC0!1 values were
13.4+5.8, 133.9+35.9 and 417.1+56.2 mg.h/L for 50 mg/kg,
100 mg/kg and 150 mg/kg rifampicin, respectively.
The mean Cmax values of pyrazinamide were 80.4+11.1,
165.0+43.6 and 268.7+93 mg/L following dosing with
200 mg/kg, 300 mg/kg and 400 mg/kg pyrazinamide, respect-
ively. Corresponding AUC0!1 values for pyrazinamide were
143+26.6, 378.1+19.7 and 607+209.7 mg.h/L for 200 mg/kg,
300 mg/kg and 400 mg/kg pyrazinamide, respectively (Table 1).
In the absence of extensive pharmacodynamic data for
rifampicin and pyrazinamide, we chose AUC as the PK parameter
on which to model human drug exposure in the current study.
Therefore 100 mg/kg rifampicin and 300 mg/kg pyrazinamide
were chosen to accompany 60 mg/kg isoniazid
20 for treatment of
guinea pigs. It should be noted that the Cmax as well as AUC
values for100 mg/kg rifampicininguineapigs closelyapproximate
the corresponding values in humans and mice (Table 1). Although
the Cmax of 300 mg/kg pyrazinamide in guinea pigs is 4-fold
higher than the corresponding value in humans, it very closely
approximates the Cmax of 150 mg/kg pyrazinamide in the mouse,
and the AUC of 300 mg/kg pyrazinamide in guinea pigs is very
similar to the corresponding values in mice (Table 1), thus permit-
ting a direct comparison of the sterilizing activity of 100 mg/kg
rifampicinþ60 mg/kg isoniazidþ300 mg/kg pyrazinamide in
guinea pigs with that of the standard regimen 10 mg/kg
rifampicinþ25 mg/kgisoniazidþ150 mg/kgpyrazinamideinmice.
In order to determine if sequential administration of rifampi-
cin followed by isoniazid/pyrazinamide could avoid an effect on
the PK parameters of isoniazid and pyrazinamide, as in mice,
19
guinea pigs received concurrent dosing with 60 mg/kg isoniazid
and 300 mg/kg pyrazinamide 1 h after dosing with 100 mg/kg
rifampicin. As shown in Table 1, under these sequential dosing
conditions, rifampicin did not have a signiﬁcant effect on the
Cmax of isoniazid or pyrazinamide, and the AUC0!1 of each of
these drugs was very mildly increased.
Bactericidal activity of rifampicin/isoniazid/
pyrazinamide in guinea pigs versus mice
On the day after aerosol infection (Day 213 of treatment),
3.4+0.3 log10 cfu and 4.7+0.4 log10 cfu of wild-type
M. tuberculosis CDC1551 were present in the lungs of mice and
Table 1. Comparison of anti-TB drug PK in guinea pigs, mice and humans
Test species Drug dosage (mg/kg) Cmax (mg/L) Tmax (h) t1/2 (h) AUC0!1 (mg.h/L)
Isoniazid
guinea pig
a 30 9.0+3.2 0.9+0.1 1.4+0.3 22.9+5.5
guinea pig
a 60 16.8+3.5 0.8+0.03 0.9+0.2 34.1+4.9
guinea pig 60
b 16.4+15.7 2.4+0.3 2.1+0.9 45.5+35.2
mouse
c 25 19.4+2.0 0.5 1.6+0.2 29.4+0.5
human
d 6.2+6
rapid acetylators 5.4+20 1.1+0.5 1.5+0.31 19.9+6.1
slow acetylators 7.1+1.9 1.1+0.6 3.7+0.59 48.2+1.5
Rifampicin
guinea pig 50 2.9+2.0 2.0+0.01 2.4+1.8 13.4+5.8
guinea pig 100 15.9+2.9 2.9+1.1 5.2+1.0 133.9+35.9
guinea pig 100
b 14.6+4.4 1.9+1.0 4.9+4.5 141.4+127.7
guinea pig 150 40.5+5.2 2.7+1.2 5.9+0.3 417.1+56.2
mouse
c 10 16.2+3.5 1–4 5.2+3.2 165+37.0
human
d 10–15 14.9 2.8 2.5 117.9
Pyrazinamide
guinea pig 200 80.4+11.1 0.7+0.3 0.7+0.1 143+26.6
guinea pig 300 165.0+43.6 0.9+0.2 1.0+0.01 378.1+19.7
guinea pig 300
b 145.3+65.0 2.5+0.02 1.2+0.1 399.5+190.5
guinea pig 400 268.7+93 0.63+0.1 0.7+0.03 607+209.7
mouse
c 150 153 0.5 1.3 350
human
d 27+4 38.7+5.9 1+0 9.6+1.8 520+101
aDenotes data from reference 15.
bDenotes dose given as part of rifampicin/isoniazid/pyrazinamide combination; in each case, rifampicin was given 60 min prior to the administration of
the two companion drugs.
cDenotes single-dose PK data obtained as part of rifampicin/isoniazid/pyrazinamide combination in BALB/c mice;
32 standard deviations are not pro-
vided for pyrazinamide values in this reference.
dDenotes data from reference 29; standard deviations are not provided for rifampicin values in this reference.
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JACguinea pigs, respectively. In each species, the bacilli grew expo-
nentially to 7.4+0.1 log10 cfu and 8.7+0.2 log10 cfu on Day 0
of treatment in mice and guinea pigs, respectively. Despite the
higher bacillary burden in guinea pigs, the bacillary density in
the lungs of each species was very similar (7.9+0.1 log10 cfu/g
of lung tissue in mice and 7.7+0.2 log10 cfu/g of lung tissue in
guinea pigs).
The combination of 100 mg/kg rifampicinþ60 mg/kg
isoniazidþ300 mg/kg pyrazinamide administered ﬁve times
weekly had very potent bactericidal activity during the ﬁrst
14 days of treatment in guinea pigs, as lung cfu declined by an
average of 5.4 log10 cfu (Figure 1). In contrast, 10 mg/kg
rifampicinþ25 mg/kg isoniazidþ150 mg/kg pyrazinamide given
ﬁve times weekly had much more modest bactericidal activity
in mouse lungs during that time period, as lung bacillary
counts declined by an average of only 1.3 log10 cfu. At Month
1, 14 days after the dosing regimen was switched to twice
weekly, guinea pig lung cfu increased slightly and remained rela-
tively stable after 2 months of treatment (4.2+1.4 log10). Sur-
prisingly, guinea pig lungs became culture-negative after
3 months of treatment and remained culture-negative at
Month 4, Month 5 and Month 6 of treatment (Figure 1).
Guinea pig lung weights increased from 2.2+0.2 g on the day
after infection (Day 213 of treatment) to 10.4+0.8 g at treat-
ment initiation, although there was no gross evidence of inﬂam-
mation. By Day 28 of treatment, gross examination of guinea pig
lungs revealed foci of inﬂammation without discrete tubercles
and normalized lung weights were 2.4+0.2 g. By Month 4 of
treatment, guinea pig lung weights were 2.2+0.4 g and there
was gradual improvement in lung inﬂammation grossly (data
not shown).
In mice, although the rifampicin/isoniazid/pyrazinamide
regimen given twice weekly continued to have activity, it was sig-
niﬁcantly less potent than in guinea pig lungs. Lung cfu declined
by 1 log10 cfu per month and all ﬁve mouse lungs tested
remained culture-positive after 6 months of treatment with an
average bacillary burden of 0.3+0.1 log10 cfu (Figure 1). These
results are very similar to our previous experience with this
regimen in mice.
5
Sterilizing activity of rifampicin/pyrazinamide/isoniazid
in guinea pigs versus mice
Groups of 10 guinea pigs and 30 mice were held following
5 months and 6 months of rifampicin/isoniazid/pyrazinamide
treatment in order to assess culture-positive relapse rates.
When assessed 3 months after completion of treatment, not a
single guinea pig exhibited culture-positive relapse after treat-
ment was stopped at Month 5 and Month 6 (Table 2). In contrast,
93% (28/30) and 69% (20/29) of mice were still culture-positive
3 months after treatment was stopped at Month 5 and Month
6, respectively, of equivalent rifampicin/isoniazid/pyrazinamide
treatment.
Toxicity of daily rifampicin/isoniazid/pyrazinamide in
guinea pigs
Soon after initiation of treatment with rifampicin/isoniazid/pyra-
zinamide given ﬁve times weekly, the majority of guinea pigs
showed signs of toxicity, including weight loss, raised fur and
reduced activity. By Day 14 of treatment, 7 of 61 treated
guinea pigs had died, each showing evidence of colonic disten-
sion at necropsy. In contrast, all mice survived without evidence
of toxicity during the same time period. Several faecal samples
from three affected guinea pigs were submitted to the Clinical
Microbiology Laboratory of Johns Hopkins Hospital. All tests,
including Clostridium difﬁcile antigen and toxin, and anaerobic
cultures were negative. During the third week of treatment (the
week after dosing frequency was reduced to twice weekly),
three additional guinea pigs died, but by the fourth week of treat-
ment all animals began to gain weight and did not further
succumb to drug-related morbidity during the remainder of the
experiment. Mean guinea pig weights increased from
372.2+46.5 g to 554.8+82.5 g between Month 1 and Month 3
of treatment. Daily administration of rifampicin/isoniazid/
pyrazinamide did not result in mortality or clinically apparent
morbidity in mice.
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Figure 1. Human-equivalent dosing of rifampicin/isoniazid/pyrazinamide
given predominantly twice weekly has greater bactericidal activity
against M. tuberculosis in guinea pig lungs relative to mouse lungs.
Chemotherapy with the combination regimen was initiated on Day 14
after aerosol infection in each species, and was administered daily
(5 days/week) for the ﬁrst 14 days of treatment, and then twice weekly
for the remainder of treatment. Animals received human-equivalent
doses of rifampicin and isoniazid during the continuation phase of
chemotherapy. In guinea pigs, the following doses were used: 100 mg/
kg rifampicin; 60 mg/kg isoniazid; and 300 mg/kg pyrazinamide. In
mice, the following doses were used: 10 mg/kg rifampicin; 25 mg/kg
isoniazid; and 150 mg/kg pyrazinamide.
Table 2. Sterilizing activity of a predominantly twice-weekly regimen of
rifampicin/isoniazid/pyrazinamide in guinea pig and mouse lungs
Animal
species
Culture positivity at 5 (þ3)
a
months, no. of animals (%)
Culture positivity at 6 (þ3)
a
months, no. of animals (%)
Guinea pig 0/10 (0) 0/10 (0)
Mouse 28/30 (93) 20/29 (69)
a5( þ3) and 6 (þ3) indicate that animals were sacriﬁced 3 months after
completing 5 and 6 months, respectively, of rifampicin/isoniazid/
pyrazinamide treatment.
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The main ﬁnding of this study is that rifampicin/isoniazid/pyrazi-
namide treatment administered at human-equivalent doses was
much more potent against acute TB infection in guinea pigs than
in mice. The difference in treatment efﬁcacy cannot be explained
by differences in drug exposure or by the bacillary burden at
treatment initiation in the two animal models. In each model,
drug doses were equivalent and the bacillary burden/g of
tissue was the same in both models.
The dosing regimen in our study mirrors that of the ‘Denver
regimen’, in which 6 month treatment consisting of rifampicin/
isoniazid/pyrazinamide with streptomycin or ethambutol is
given for 2 months (daily dosing for the ﬁrst 2 weeks and twice
weekly thereafter) followed by twice-weekly rifampicin/isoniazid
for an additional 4 months.
7 In the original clinical study using
this regimen, only two relapses were noted among 101 patients
enrolled. However, more recent data suggest that intermittent
dosing during the initial phase of treatment may lead to unac-
ceptably high relapse rates, especially in the presence of cavita-
tion.
21 Several trials have been performed to evaluate the
efﬁcacy of shortening the duration of treatment to 3, 4 and
5 months using more intensive treatment with rifampicin, isonia-
zid and pyrazinamide.
22 Although the initial response to therapy
vis-a `-vis culture conversion was excellent in these studies,
especially for regimens containing rifampicin and pyrazinamide,
all regimens were associated with unacceptably high relapse
rates. Compared with these clinical data, it would seem that
the guinea pig model of TB chemotherapy is overly ‘optimistic’
in predicting the response to TB treatment in humans.
However, since patients with cavitary disease are known to
have higher sputum bacillary loads than those with non-cavitary
disease,
23 it is possible that the bacillary burden in most human
TB cavities at the time of clinical presentation is signiﬁcantly
greater than that of the guinea pig non-cavitary lesions in our
studies, necessitating a longer duration of antibiotic treatment
to achieve stable cure in humans. In support of this hypothesis,
several studies have shown that a shorter duration of treatment
may be sufﬁcient to achieve acceptably low relapse rates for
smear- and culture-negative adult TB patients.
24–26 However,
contrary to the ﬁndings of these studies, a recent randomized
study showed that adults with non-cavitary pulmonary TB and
negative sputum cultures after 2 months of treatment experi-
enced signiﬁcantly more relapses when treatment was shortened
from 6 months to 4 months.
27 Another possible explanation for
the absence of relapse in guinea pigs is that this species may
be able to mount a more vigorous and effective immune response
to M. tuberculosis infection than humans, leading to enhanced
bacillary killing in the face of systemic TB chemotherapy. For
example, the inability to select katG-deﬁcient isoniazid-resistant
mutants following isoniazid monotherapy in guinea pigs,
15
whereas such mutants are readily detectable from the sputum
of infected patients, suggests the possibility that guinea pig pha-
gocytes mount a more vigorous oxidative burst than do their
human counterparts. It should be noted also that our data do
not allow us to conclude that guinea pigs were truly ‘cured’ of
TB infection since bacillary burden was not assessed in extrapul-
monary organs such as spleen or liver, and because of the rela-
tively limited numbers of animals used to assess relapse rates.
Another possible explanation for the potent activity of
rifampicin/isoniazid/pyrazinamide in guinea pigs observed in
this study may be that the PK parameters chosen to model
human drug exposure were incorrect. For example, it has been
suggested that Cmax, rather than AUC, may be the PK parameter
most closely related to isoniazid activity in humans.
28 Although
the Cmax of 60 mg/kg isoniazid used for guinea pigs in this
study is more than double that of human slow acetylators,
29
this value is lower than that of 25 mg/kg isoniazid used in the
mouse comparison arm, and thus cannot explain the superior
activity of rifampicin/isoniazid/pyrazinamide in guinea pigs com-
pared with mice. On the other hand, the Cmax values of the
rifampicin and pyrazinamide doses chosen for guinea pigs in
this study match well with the corresponding values of the rifam-
picin and pyrazinamide doses used in the mouse group. The dra-
matic efﬁcacy of rifampicin/isoniazid/pyrazinamide in guinea pigs
may also be partially explained by the acute form of our exper-
imental disease that may have rendered bacilli more susceptible
to killing by antibiotics. In support of this hypothesis, a recent
study reported that guinea pigs aerosol-infected with 20–30
bacilli and receiving rifampicin/isoniazid/pyrazinamide treatment
after a 30 day incubation period showed only a 1.7 log10
reduction in lung cfu after 6 weeks of treatment.
30 However,
the limited activity of rifampicin/isoniazid/pyrazinamide reported
in that study may be related at least in part to the lower doses
of drugs used (12 mg/kg rifampicin, 10 mg/kg isoniazid and
25 mg/kg pyrazinamide). To clarify this issue we are currently
studying the activity of human-equivalent doses of rifampicin,
isoniazid and pyrazinamide in a chronic, low-dose aerosol
infection model of guinea pig TB.
The gastrointestinal toxicity in guinea pigs associated with
human-equivalent dosing of rifampicin/isoniazid/pyrazinamide
presents a signiﬁcant challenge for future TB chemotherapy
studies in this species. Although numerous tests did not identify
it in stool specimens of affected animals in the current study,
C. difﬁcile has been reported to cause similar colitis in guinea
pigs following treatment with broad-spectrum antibiotics.
31 An
alternative explanation is that isoniazid, pyrazinamide or the
combination rifampicin/isoniazid/pyrazinamide may have a
direct toxic effect on the gastrointestinal tract of guinea pigs.
Future long-term combination chemotherapy studies in guinea
pigs will probably require intermittent dosing of the control
regimen rifampicin/isoniazid/pyrazinamide, reduction in the
mg/kg dose of one or more of the drugs in this regimen or con-
comitant administration of probiotic agents.
Our ﬁndings have important implications for the use of
alternative animal models in assessing the potential sterilizing
activity of new anti-TB drugs and drug combinations and for
modelling M. tuberculosis persistence. Any potential advantages
of such models must be weighed against practical consider-
ations, including increased costs and drug-related toxicity.
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